I am a Medical Research Council Research Training Fellow combining training in laboratory science with clinical training in Gastroenterology and Hepatology. My major clinical interest is in hepatitis C virus (HCV) infection, particularly following liver transplantation.
I am co-ordinating a proof of principle phase I study of a first in class HCV entry inhibitor (ITX5061 in liver transplant recipients: clinicaltrials.gov NCT01292824) that was partly characterised in the McKeating Lab. This study has the potential to address the unmet need for therapeutics preventing HCV recurrence for patients undergoing transplantation for HCV related liver disease and liver cancer.
In the laboratory I am studying the role of the sinusoidal endothelium of the liver in HCV infection. When blood enters the liver carrying HCV particles these first encounter the endothelium before seeing hepatocytes, the major reservoir for HCV in the liver. The functions of sinusoidal endothelial cells are not well understood in viral infection. The mechanism by which they interact with hepatocytes during infection might provide insights into both disease pathogenesis as well as normal liver function.
I can’t start the day without reading these first…
HCV Research Group
Institute of Biomedical Research,
School of Immunity and Infection,
College of Medical and Dental Sciences,
University of Birmingham, Birmingham B15 2TT UK
E-mail: Ian Rowe
PubMed listed Publications
Contacting NCBI Entrez ...